RecruitingPhase 1NCT06265688

First In Human Study of CX-2051 in Advanced Solid Tumors

An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors

Sponsor

CytomX Therapeutics

Enrollment

160 participants

Start Date

Apr 2, 2024

Study Type

INTERVENTIONAL

Conditions

Solid Tumor, Adult

Summary

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Measurable disease per RECIST v1.1
Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue

Exclusion Criteria8

Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated
Known active central nervous system (CNS) involvement by malignancy
Systemic anticancer treatment, radiotherapy, or investigational agent(s) within 14 days prior to C1D1
Previous treatment with antibody-drug conjugates (ADCs) with Topo-I inhibitor payload
Major surgery (requiring general anesthesia) within 4 weeks prior to C1D1
Elevated baseline laboratory values
Serious concurrent illness
Pregnant or breast feeding